The Overview
Nurix Therapeutics announced the enrollment of the first patient in its Phase 1b/2 NX-5948-203 study. This trial evaluates bexobrutideg, an investigational oral Bruton’s tyrosine kinase (BTK) degrader, in combination with venetoclax, a standard-of-care BCL2 inhibitor, for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The initial cohort focuses on relapsed/refractory CLL, with potential expansion to first-line CLL and other B-cell malignancies. The study, conducted under a global collaboration with Roche, aims to assess safety, tolerability, and clinical activity to inform future registrational development strategies.
Knolens Analysis
At a Glance
| Indication | Chronic Lymphocytic Leukemia |
| Drug | bexobrutideg |
| Mechanism of Action | Bruton’s tyrosine kinase (BTK) degrader |
| Company | Nurix Therapeutics, Inc. |
| Trial Phase | Phase 1b/2 |
| Trial Acronym | NX-5948-203 |
| NCT ID | NCT07520006 |
| Category | Clinical Trial Event |
| Sub Category | Trial Initiation / First Patient In (FPI) |
| Therapeutic Area | Oncology |
| Combination Partner | venetoclax |
| Collaboration Partner | Roche |
| Combination Partner Class | BCL2 inhibitor |
| Patient Subpopulation | relapsed/refractory CLL, treatment-naïve CLL |
| Future Combination Partners | rituximab, obinutuzumab |
| Press Release Date | October 06, 2026 |
| Drug Characteristics | oral, brain-penetrant |
| Other Clinical Trials | DAYBreak CLL-201 (NCT07221500), DAYBreak CLL-306 (NCT07516093), NX-5948-301 (NCT05131022) |
Nurix Enrolls First Patient in Bexobrutideg/Venetoclax CLL Study
Nurix Therapeutics announced the enrollment of the first patient in its Phase 1b/2 NX-5948-203 study. This trial evaluates bexobrutideg, an investigational oral Bruton’s tyrosine kinase (BTK) degrader, in combination with venetoclax, a standard-of-care BCL2 inhibitor, for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The initial cohort focuses on relapsed/refractory CLL, with potential expansion to first-line CLL and other B-cell malignancies. The study, conducted under a global collaboration with Roche, aims to assess safety, tolerability, and clinical activity to inform future registrational development strategies.
- The NX-5948-203 study is a Phase 1b/2 trial designed to evaluate the safety, tolerability, and clinical activity of bexobrutideg in combination with venetoclax. It initially targets relapsed/refractory CLL/SLL patients, with plans to expand to first-line CLL and potentially other B-cell malignancies. The data from this trial are crucial for informing future registrational development strategies across various lines of therapy in CLL.
- Bexobrutideg is highlighted as an investigational oral, brain-penetrant, highly selective BTK degrader with a differentiated mechanism of action. Its robust single-agent activity and favorable tolerability make it an attractive candidate for combination approaches, aiming to deliver deep, durable responses with fixed-duration therapy in B-cell malignancies.
- This combination study is part of a comprehensive clinical development program for bexobrutideg. Other ongoing trials include the pivotal single-arm Phase 2 DAYBreak CLL-201 study in relapsed/refractory CLL, the randomized Phase 3 DAYBreak CLL-306 trial comparing it to pirtobrutinib, and the Phase 1a/1b NX-5948-301 study in relapsed/refractory B-cell malignancies.
Frequently Asked Questions
Are there any natural cures for CLL?
There are no scientifically validated natural cures for Chronic Lymphocytic Leukemia (CLL). While some complementary and alternative medicine (CAM) approaches may support symptom management or improve quality of life, they do not eradicate the disease or serve as a substitute for conventional medical therapies. Patients should always discuss any natural remedies with their oncology team to ensure safety and avoid potential interactions.
How bad is a diagnosis of CLL?
A diagnosis of Chronic Lymphocytic Leukemia (CLL) carries a highly variable prognosis, ranging from indolent disease requiring no immediate treatment for many years to more aggressive forms necessitating prompt intervention. While incurable, significant advancements in targeted therapies, such as BTK inhibitors and BCL-2 inhibitors, have dramatically improved progression-free and overall survival, transforming it into a manageable chronic condition for many patients. Prognostic factors like *IGHV* mutational status, *TP53* mutation, and del(17p) are critical in determining disease aggressiveness and guiding treatment decisions.
How to stop CLL from progressing?
For early-stage, asymptomatic CLL, a "watch and wait" approach is standard, as active intervention does not improve overall survival and carries treatment-related risks. When treatment is indicated due to active disease or symptoms, targeted therapies such as BTK inhibitors (e.g., ibrutinib, acalabrutinib, zanubrutinib) and BCL-2 inhibitors (e.g., venetoclax, often combined with anti-CD20 antibodies) are highly effective. These agents aim to control disease activity, reduce tumor burden, and achieve deep, durable remissions, thereby preventing or reversing symptomatic progression and improving patient outcomes.
What is the recommended diet for people with chronic lymphocytic leukemia (CLL)?
There is no specific, evidence-based diet exclusively recommended for chronic lymphocytic leukemia (CLL). Instead, patients are generally advised to follow a balanced, nutrient-dense diet rich in fruits, vegetables, whole grains, and lean proteins to support overall health, immune function, and manage potential treatment-related side effects. Limiting processed foods, excessive sugar, and unhealthy fats is also typically recommended. Individualized nutritional guidance may be necessary based on treatment regimens and specific patient needs.
Is it possible to live with CLL for 30 years?
A significant proportion of patients with Chronic Lymphocytic Leukemia (CLL) can live for 30 years or more, particularly those with indolent disease and favorable prognostic markers. The natural history of CLL is highly variable, with some individuals experiencing very slow progression or remaining in a watch-and-wait phase for decades without requiring active treatment. Advances in targeted therapies and improved supportive care have further extended life expectancy, making long-term survival increasingly achievable for a broader range of patients.
What is the average survival rate for patients with chronic lymphocytic leukemia (CLL)?
The average 5-year relative survival rate for patients with chronic lymphocytic leukemia (CLL) is approximately 88-90% for all stages combined, based on data from 2013-2019. This rate has significantly improved over recent decades due to advancements in diagnostic techniques and the introduction of novel targeted therapies. Individual prognosis can vary based on patient-specific factors, disease characteristics, and treatment response.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
